Volume 14, Number 6—June 2008
Dispatch
High Failure Rates of Melarsoprol for Sleeping Sickness, Democratic Republic of Congo
Jo Robays*
, Gaspard Nyamowala†‡, Claude Sese†, Victor Betu Ku Mesu Kande†, Pascal Lutumba†§, Wim Van der Veken¶, and Marleen Boelaert*
, Gaspard Nyamowala†‡, Claude Sese†, Victor Betu Ku Mesu Kande†, Pascal Lutumba†§, Wim Van der Veken¶, and Marleen Boelaert*
Table 2
Characteristics of 959 patients who experienced relapse after treatment with melarsoprol, Equateur Nord Province, 2001–2003
| Characteristic | No. (%) |
|---|---|
| Sex | |
| M | 433 (45.2) |
| F |
526 (54.8) |
| Age | |
| >1–11mo | 1 (0.1) |
| 12–59 mo | 13 (1.4) |
| 5–59 y | 936 (97.6) |
| >60 y |
9 (0.9) |
| Stage of disease | |
| First | 46 (4.8) |
| Second | 782 (81.5) |
| Unknown |
131 (13.7) |
| Parasites found | 259 (27.0) |
Page created: July 09, 2010
Page updated: July 09, 2010
Page reviewed: July 09, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.